Hydroxychloroquine

Generic Name: Hydroxychloroquine

Brand Names: Plaquenil, Sovuna

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₆ClN_₃O

CAS Number: 118-42-3

Unique Ingredient Identifier: 4QWG6N8QKH

Background: Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like chloroquine. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxi...

Indication: Hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported, treatment of uncomplicated malaria (caused by P. falciparum, P. malariae, P. ovale, or P. vivax), chronic discoid lupus erythematosus, systemic lupus erythematosus, acute rheumatoid arthritis, and chronic rheumatoid arthritis.

Associated Conditions: Acute Rheumatoid Arthritis, Malaria, Porphyria Cutanea Tarda, Q Fever, Sjogren's Syndrome (SS), Systemic Lupus Erythematosus, Uncomplicated Malaria caused by Plasmodium Vivax, Uncomplicated Malaria caused by Plasmodium malariae, Uncomplicated Malaria caused by Plasmodium ovale, Chronic Discoid Lupus Erythematosus (DLE), Chronic Rheumatoid Arthritis, Uncomplicated Malaria caused by Plasmodium falciparum

Associated Therapies: -

Clinical Trials

Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis

Phase 4

Not yet recruiting

Conditions: Sarcoidosis, Pulmonary

Interventions: Drug: Hydroxychloroquine
Drug: Placebo

First Posted Date: 2023-05-03

Last Posted Date: 2024-03-06

Lead Sponsor: Hospices Civils de Lyon

Target Recruit Count: 140

Registration Number: NCT05841758

Locations: 🇫🇷
Service de médecine interne - Hôpital de la Croix Rousse, Lyon, France
🇫🇷
Service de medecine interne - Hôpital Saint Eloi, Montpellier, France
🇫🇷
Service de medecine interne - Hôpital Nord, Saint-Étienne, France

and more 16 locations

Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease

Phase 3

Recruiting

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: Placebo
Drug: Hydroxychloroquine

First Posted Date: 2023-04-05

Last Posted Date: 2024-06-28

Lead Sponsor: NYU Langone Health

Target Recruit Count: 330

Registration Number: NCT05799378

Locations: 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸
Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, United States
🇺🇸
VA NY Harbor Healthcare System, New York, New York, United States

and more 7 locations

Hydroxychloroquine in Colchicine-Resistant Glucocorticoid-Dependent Idiopathic Recurrent Pericarditis

Phase 3

Not yet recruiting

Conditions: Pericarditis Idiopathic Recurrent

Interventions: Drug: Colchicine
Drug: Hydroxychloroquine

First Posted Date: 2023-02-21

Last Posted Date: 2023-02-22

Lead Sponsor: Hippocration General Hospital

Target Recruit Count: 30

Registration Number: NCT05737680

Locations: 🇬🇷
"Hippokration" General Hospital of Athens, Athens, Attiki, Greece

Using Hydroxychloroquine to Treat Nonalcoholic Steatohepatitis

Recruiting

Conditions: Nonalcoholic Steatohepatitis

First Posted Date: 2023-02-17

Last Posted Date: 2023-03-02

Lead Sponsor: National Taiwan University Hospital

Target Recruit Count: 150

Registration Number: NCT05733897

Locations: 🇨🇳
Graduate Institute of Pharmacology, College of Medicine, National Taiwan University, Taipei, Taiwan
🇨🇳
National Taiwan University Hospital, Taipei, Taiwan

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Phase 2

Recruiting

Conditions: Advanced Pancreatic Carcinoma
Metastatic Ovarian Carcinoma
Refractory Lung Adenocarcinoma
Refractory Urothelial Carcinoma
Stage II Pancreatic Cancer AJCC v8
Stage III Ovarian Cancer AJCC v8
Advanced Biliary Tract Carcinoma
Advanced Lung Adenocarcinoma
Advanced Malignant Solid Neoplasm
Advanced Urothelial Carcinoma

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Devimistat
Drug: Fluorouracil
Drug: Gemcitabine Hydrochloride
Drug: Hydroxychloroquine
Procedure: Magnetic Resonance Imaging

First Posted Date: 2023-02-17

Last Posted Date: 2023-03-10

Lead Sponsor: Northwestern University

Target Recruit Count: 94

Registration Number: NCT05733000

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

Evaluation of Hydroxychloroquine to Prevent CIPN

Phase 2

Withdrawn

Conditions: Gynecologic Cancer
Breast Cancer
Early-stage Breast Cancer
Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy

Interventions: Drug: Hydroxychloroquine

First Posted Date: 2023-01-19

Last Posted Date: 2024-03-08

Lead Sponsor: University of Arizona

Registration Number: NCT05689359

Tacrolimus for Thrombocytopenia in SS

Phase 2

Not yet recruiting

Conditions: Sjogren Syndrome With Other Organ Involvement

Interventions: Drug: Hydroxychloroquine
Drug: Tacrolimus

First Posted Date: 2023-01-10

Last Posted Date: 2023-01-10

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 54

Registration Number: NCT05678335

Multi-omics Studies on the Efficacy of Telitacicept in Chinese SLE Patients

Phase 4

Recruiting

Conditions: Systemic Lupus Erythematosus

Interventions: Biological: Telitacicept
Drug: Hydroxychloroquine
Drug: Prednisone
Drug: Methylprednisolone
Drug: Cyclophosphamide
Drug: Mycophenolate Mofetil
Drug: Tacrolimus

First Posted Date: 2022-12-27

Last Posted Date: 2024-01-17

Lead Sponsor: Fen Li

Target Recruit Count: 30

Registration Number: NCT05666336

Locations: 🇨🇳
Department of Rheumatology and Immunology, Xiangya Second Hospital, Central South University, Changsha, Hunan, China

The Clinical Features and Pregnancy Outcomes of RA Patients

Recruiting

Conditions: Pregnancy Related
Rheumatoid Arthritis

Interventions: Drug: Prednisone
Drug: Hydroxychloroquine
Drug: CertolizumabPegol injection

First Posted Date: 2022-12-15

Last Posted Date: 2022-12-15

Lead Sponsor: Qilu Hospital of Shandong University

Target Recruit Count: 100

Registration Number: NCT05651373

Locations: 🇨🇳
Qilu Hospital, Jinan, Shandong, China

Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE

Recruiting

Conditions: Antiphospholipid Syndrome

Interventions: Drug: Telitacicept
Drug: Rituximab
Drug: Aspirin
Drug: Hydroxychloroquine
Drug: Warfarin
Drug: Prednisone

First Posted Date: 2022-12-09

Last Posted Date: 2022-12-09

Lead Sponsor: Qilu Hospital of Shandong University

Target Recruit Count: 80

Registration Number: NCT05644210

Locations: 🇨🇳
Qilu Hospital, Jinan, Shandong, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy